Steven J. Isakoff
About
Steven J. Isakoff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Steven J. Isakoff has authored 176 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Oncology, 74 papers in Pulmonary and Respiratory Medicine and 66 papers in Cancer Research. Recurrent topics in Steven J. Isakoff's work include Cancer Treatment and Pharmacology (57 papers), Advanced Breast Cancer Therapies (55 papers) and HER2/EGFR in Cancer Research (45 papers). Steven J. Isakoff is often cited by papers focused on Cancer Treatment and Pharmacology (57 papers), Advanced Breast Cancer Therapies (55 papers) and HER2/EGFR in Cancer Research (45 papers). Steven J. Isakoff collaborates with scholars based in United States, Spain and United Kingdom. Steven J. Isakoff's co-authors include Aditya Bardia, Edward Y. Skolnik, Kishore K. Wary, Fabrizio Mainiero, Eugene E. Marcantonio, Filippo G. Giancotti, Mark A. Lemmon, José Baselga, Leif W. Ellisen and Lecia V. Sequist and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.
In The Last Decade
Steven J. Isakoff
166 papers receiving 9.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Steven J. Isakoff United States | 37 | 5.0k | 3.9k | 2.8k | 2.0k | 1.2k | 176 | 9.3k | ||
| Livio Trusolino Italy | 51 | 4.4k 0.9× | 4.9k 1.3× | 2.2k 0.8× | 1.7k 0.9× | 942 0.8× | 135 | 10.2k | ||
| Gaorav P. Gupta United States | 28 | 4.4k 0.9× | 5.5k 1.4× | 2.9k 1.0× | 1.1k 0.6× | 817 0.7× | 76 | 9.5k | ||
| Don X. Nguyen United States | 26 | 4.0k 0.8× | 4.0k 1.0× | 2.4k 0.8× | 1.6k 0.8× | 720 0.6× | 55 | 8.1k | ||
| Paula D. Bos United States | 17 | 4.2k 0.8× | 5.1k 1.3× | 3.5k 1.2× | 1.3k 0.6× | 691 0.6× | 33 | 9.5k | ||
| Suzanne A. Eccles United Kingdom | 52 | 3.5k 0.7× | 5.1k 1.3× | 2.1k 0.8× | 878 0.4× | 872 0.7× | 140 | 8.9k | ||
| Jahn M. Nesland Norway | 53 | 4.5k 0.9× | 5.5k 1.4× | 2.3k 0.8× | 3.0k 1.5× | 786 0.7× | 203 | 11.4k | ||
| Gunhild M. Mælandsmo Norway | 49 | 3.3k 0.6× | 5.1k 1.3× | 2.4k 0.8× | 1.3k 0.7× | 507 0.4× | 219 | 8.7k | ||
| Christoph A. Klein Germany | 45 | 4.6k 0.9× | 3.4k 0.9× | 3.2k 1.1× | 1.3k 0.6× | 579 0.5× | 152 | 8.8k | ||
| Peter M. Siegel Canada | 53 | 7.0k 1.4× | 9.0k 2.3× | 3.6k 1.3× | 1.6k 0.8× | 1.2k 1.0× | 148 | 14.7k | ||
| Jahn M. Nesland Norway | 53 | 3.7k 0.7× | 3.5k 0.9× | 2.3k 0.8× | 2.2k 1.1× | 480 0.4× | 194 | 9.1k |
Countries citing papers authored by Steven J. Isakoff
Since
Specialization
Citations
This map shows the geographic impact of Steven J. Isakoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven J. Isakoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven J. Isakoff more than expected).
Fields of papers citing papers by Steven J. Isakoff
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Steven J. Isakoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven J. Isakoff. The network helps show where Steven J. Isakoff may publish in the future.
Co-authorship network of co-authors of Steven J. Isakoff
This figure shows the co-authorship network connecting the top 25 collaborators of Steven J. Isakoff. A scholar is included among the top collaborators of Steven J. Isakoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven J. Isakoff. Steven J. Isakoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Edmonds, Christine E., Brian N. Dontchos, Gary Wang, et al.. (2024). A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance. Breast Cancer Research. 26(1). 107–107.
2.
Dent, Rebecca, Sung‐Bae Kim, Mafalda Oliveira, et al.. (2024). Ipatasertib plus Paclitaxel for Patients with PIK3CA / AKT1 / PTEN -Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical Cancer Research. 30(19). 4329–4338.
3.
Juric, Dejan, Kathryn Post, Steven J. Isakoff, et al.. (2023). Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. The Oncologist. 28(4). 358–363.
4.
Sella, Tal, Yue Zheng, Nabihah Tayob, et al.. (2022). Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). npj Breast Cancer. 8(1). 127–127.
5.
Turner, Nicholas C., Rebecca Dent, Joyce O’Shaughnessy, et al.. (2021). Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Research and Treatment. 191(3). 565–576.
6.
Parsons, Heather A., Erin Macrae, Hao Guo, et al.. (2021). Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology. 5(5). 896–903.
7.
Vaz-Luís, Inês, Tianyu Li, Nabihah Tayob, et al.. (2021). A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. 189(2). 411–423.
8.
Shi, Zhen, Julia Wulfkuhle, Małgorzata Nowicka, et al.. (2021). Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research. 28(5). 993–1003.
9.
Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413.
10.
Koh, Siang‐Boon, Kenneth N. Ross, Steven J. Isakoff, et al.. (2021). RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research. 27(17). 4883–4897.
11.
Smith, Barbara L., Bridget N. Kelly, Michelle C. Specht, et al.. (2020). A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Research and Treatment. 183(3). 515–524.
12.
Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262.
13.
Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451.
14.
Nixon, Mellissa J., Luigi Formisano, Ingrid A. Mayer, et al.. (2019). PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. npj Breast Cancer. 5(1). 31–31.
15.
Marks, Dustin H., Jean‐Phillip Okhovat, Dina Hagigeorges, et al.. (2019). The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. Breast Cancer Research and Treatment. 175(2). 267–276.
16.
Telli, Melinda L., Charles C. Chu, Sunil Badve, et al.. (2019). Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research. 26(11). 2704–2710.
17.
Magbanua, Mark Jesus M., Hope S. Rugo, Denise M. Wolf, et al.. (2018). Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clinical Cancer Research. 24(6). 1486–1499.
18.
Keenan, Tanya E., Beverly Moy, Edmund A. Mroz, et al.. (2015). Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology. 33(31). 3621–3627.
19.
Blackwell, Kimberly, Howard A. Burris, Patricia Gómez, et al.. (2015). Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment. 154(2). 287–297.
20.
Yu, Min, Aditya Bardia, Ben S. Wittner, et al.. (2013). Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition. Science. 339(6119). 580–584.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Livio Trusolino Breakdown of academic impact, for papers by Gaorav P. Gupta Breakdown of academic impact, for papers by Don X. Nguyen Breakdown of academic impact, for papers by Paula D. Bos Breakdown of academic impact, for papers by Suzanne A. Eccles Breakdown of academic impact, for papers by Jahn M. Nesland Breakdown of academic impact, for papers by Gunhild M. Mælandsmo Breakdown of academic impact, for papers by Christoph A. Klein Breakdown of academic impact, for papers by Peter M. Siegel Breakdown of academic impact, for papers by Jahn M. Nesland